Related Experiment Video
Updated: Jul 11, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Is it time to stop treating dyslipidaemia with fibrates?
Jocelyne R Benatar1, Ralph A Stewart
1Cardiovascular Research Unit, Green Lane Clinical Centre, Green Lane, Auckland. JBenatar@adhb.govt.nz
Aim:
To determine whether evidence from randomised clinical trials supports the use of fibrates to reduce non-fatal and fatal cardiovascular events in patients with dyslipidaemia.
Method:
Review of randomised clinical trials of fibrates that assess clinical outcomes.
Result:
In clinical trials which have which have included over 40,000 patients there was no difference in all cause mortality for patients randomised to a fibrate compared to placebo. Treatment with a fibrate was associated with a small reduction in the risk of non-fatal cardiovascular events.
Discussion:
Current evidence does not support the use of fibrates to reduce cardiovascular mortality. Other proven strategies including statins, aspirin, angiotension converting enzyme (ACE) inhibitors, good blood pressure control, and lifestyle interventions should be used to reduce cardiovascular risk.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Lipids: Dietary Sources and Requirements
Inflammation
